Entity
  • Diotheris

    Created in 2020
  • BETA

    Probably non active (C)
    Several signals show that this company is not active anymore
  • Social networks

    224
  • Activities

  • Technologies

  • Entity types

  • Location

    Paris, France

    Paris

    France

  • Employees

    Scale: 2-10

    Estimated: 1

  • Engaged corporates

    1
    1 0
  • Added in Motherbase

    8 months ago
Description
  • Value proposition

    Diotheris develops anti-infective microbes to prevent bacterial infections and act against antibiotic resistance

    We create bacterial therapies of the human skin and mucosal microbiome against pathogenic bacteria. Our first suite of products (NASOFLORE line) targets Staphyloccocus aureus / MRSA (Methicillin resistant S aureus). The products based on live bacteria identified in our clinical and in vitro studies do not generate emergence of antibiotic resistance.

    antimicrobial, nose microbiome, therapeutics, LBP, Staphylococcus Aureus, and MRSA

  • Original language

    Diotheris develops anti-infective microbes to prevent bacterial infections and act against antibiotic resistance

    We create bacterial therapies of the human skin and mucosal microbiome against pathogenic bacteria. Our first suite of products (NASOFLORE line) targets Staphyloccocus aureus / MRSA (Methicillin resistant S aureus). The products based on live bacteria identified in our clinical and in vitro studies do not generate emergence of antibiotic resistance.

  • diotheris.com

    Ce domaine a été enregistré chez Gandi.net. Le propriétaire de ce domaine n'a pas encore activé de site web.

  • http://www.diotheris.com/
  • Website is disabled or domain is for sale
Corporate interactions BETA
Corporate TypeTweets Articles
SATT Paris-Saclay
SATT Paris-Saclay
Research, Startup accelerator & VC, Research Services
SATT Paris-Saclay
Research, Startup accelerator & VC, Research Services
Other

7 Jan 2023


Similar entities
Loading...
Loading...
Social network dynamics